Valexfarm

Valexfarm was a Serbia-based for-profit biotech company focused on central nervous system disorders. The company sponsored mid- to late-stage clinical trials of Remegal as adjunctive therapy for patients with refractory or partial seizures, including a Phase 2 study started in 2009 and a completed Phase 3 study started in 2012. Publicly accessible pipeline data also links Valexfarm to VLB-01/Remegal, described as a small-molecule program associated with melatonin receptor activity. Patent records indicate the company also explored small-molecule approaches for pain and neuropsychiatric disorders such as migraine, fibromyalgia, bipolar disorder, and depression. Available evidence suggests the company is no longer active, with last known public R&D activity around 2012-2013 and no marketed drug identified.